🇺🇸 FDA
Pipeline program

0.05% Voclosporin Ophthalmic Solution (VOS)

AUR-VOS-2019-01

Phase 3 small_molecule completed

Quick answer

0.05% Voclosporin Ophthalmic Solution (VOS) for Dry Eye Syndrome is a Phase 3 program (small_molecule) at Aurinia Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Aurinia Pharmaceuticals
Indication
Dry Eye Syndrome
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials